Over the weeks of protests following the death of George Floyd, much attention has been given to a few viral posts that concern the number of hours of training that are required to obtain a ...
The agreement grants Cosmo Technologies Ltd. an exclusive license for the development and commercialization of PAION's lead drug candidate, remimazolam, in the territory of the United States. Under ...
Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions Dublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: ...
Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries
Dublin, Ireland – 02 October 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (“Hikma”) today announced the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback